1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Demographics and clinical data at time of diagnosis in cohort of pediatric patients with MOGAD
n = 61
Age, median (IQR), years7 (4–11)
Female (%)34 (55.7)
Race (%)
 African American6 (9.8)
 Hispanic13 (21.3)
 White22 (36.1)
 Other14 (23.0)
 Unknown6 (9.8)
Initial clinical presentation
 Syndrome
 ADEM14 (23.0)
 ON31 (50.8)
 Myelitis12 (19.7)
Symptom
 Headache19 (31.1)
 Altered mental status12 (19.7)
 Ataxia7 (11.5)
 Fever11 (18.0)
 Seizure2 (3.3)
Anti-MOG titer, median (IQR)a1:100 (1:80–1:1000)
Relapsing disease45 (73.8)
Total episodes up to 10, median (IQR)3 (1–4)
Time to first relapse, median (IQR), months5 (2–13)
  • aTiter while acutely symptomatic during initial presentation was not available for 45 patients.